Open AccessFirst-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Author(s) -
Benjamin Solomon,
Tony Mok,
DongWan Kim,
YiLong Wu,
Kazuhiko Nakagawa,
Tarek Mekhail,
Enriqueta Felip,
Federico Cappuzzo,
Jolanda Paolini,
Tiziana Usari,
Shrividya Iyer,
Arlene Reisman,
Keith D. Wilner,
Jennifer Tursi,
Fiona Blackhall
Publication year - 2014
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1408440
Subject(s) - crizotinib , medicine , lung cancer , chemotherapy , oncology , intensive care medicine , malignant pleural effusion
The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom